Review article: induction therapy for patients with active ulcerative colitis.

Area of Science:

• Gastroenterology
• Pharmacology
• Inflammatory Bowel Disease Research

Background:

• 5-aminosalicylic acid (mesalazine) is a cornerstone therapy for ulcerative colitis.
• Conventional doses are well-tolerated, but higher doses and combination therapies are being explored for enhanced efficacy.

Purpose of the Study:

• To evaluate the effectiveness of high-dose and combination oral/rectal 5-aminosalicylic acid (mesalazine) therapy in ulcerative colitis.
• To determine optimal dosing strategies for achieving higher response and remission rates.

Main Methods:

• Review of clinical trial evidence on 5-aminosalicylic acid (mesalazine) dosing and administration routes.
• Analysis of outcomes based on dose escalation (>4 g/day) and combined oral/rectal formulations.

Main Results:

• High-dose 5-aminosalicylic acid (>4 g/day) is associated with increased response rates and earlier symptom relief.
• Combining oral and rectal 5-aminosalicylic acid formulations leads to faster and higher remission rates.
• Rectal 5-aminosalicylic acid may be sufficient for active proctitis and beneficial for extensive colitis.

Conclusions:

• Starting mild-moderate ulcerative colitis patients on at least 4 g/day of 5-aminosalicylic acid is recommended.
• Augmenting high-dose oral therapy with rectal 5-aminosalicylic acid improves remission, especially in extensive disease.
• Oral steroids may be necessary for patients not responding to high-dose 5-aminosalicylic acid within two weeks.